Skip to main content
AMLX
NASDAQ Life Sciences

Amylyx Q2 Loss Widens on Legal Costs; Five Insiders Adopt 10b5-1 Plans Ahead of Key Phase 3 Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$21.6
Mkt Cap
$2.429B
52W Low
$7.48
52W High
$22.28
52W Position info
189% above low
Off High info
3.1% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

AMLX has more than doubled off its 52-week low of $7.48.

Summary

Amylyx missed Q2 estimates with a $0.39 loss per share as legal and pre-launch costs surged. Five insiders adopted 10b5-1 plans to sell up to 395,000 shares. Cash runway extends into 2028, but all eyes are on the upcoming Phase 3 avexitide data.


Key Events · Earnings and Guidance · AMLX

  • Q2 Loss Misses Estimates

    Net loss of $43.4M ($0.39/share) vs. $41.4M loss a year ago, missing the $0.36 consensus. SG&A surged 40% to $21.9M on legal settlement costs and pre-commercialization spending.

  • Cash Reserves Decline

    Cash, equivalents, and marketable securities fell to $250.8M from $317.0M at year-end 2025. Management expects runway into 2028.

  • Insider Selling Cluster

    Five insiders — including both Co-CEOs, the CFO, the CLO, and a director — adopted new 10b5-1 plans authorizing sales of up to 395,000 shares total. Plans were adopted between April 9 and May 11, 2026.

  • Class Action Settlement Progresses

    Court preliminarily approved the $6.5M settlement of the Shih securities class action, with a final approval hearing set for September 10, 2026. A significant portion is covered by insurance.


Analysis · AMLX · Life Sciences

Amylyx posted a larger-than-expected Q2 loss of $0.39 per share, missing consensus by $0.03, as SG&A costs jumped 40% to $21.9 million — driven by the $6.5 million class action settlement and pre-commercialization spending for avexitide. Cash reserves fell to $250.8 million, still funding operations into 2028. The quarter also saw five insiders, including both Co-CEOs and the CFO, adopt new 10b5-1 trading plans authorizing sales of up to 395,000 shares. This cluster of insider selling plans, combined with the earnings miss and rising expenses, raises concerns about management's near-term outlook — especially with pivotal Phase 3 LUCIDITY data for avexitide expected in Q3 2026, a binary event that will define the company's future.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMLX was trading at $21.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $7.48 to $22.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMLX - Latest Insights

AMLX
Nov 05, 2026, 7:04 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $25.55 info
Change: -$4.45 (-15%) info
Market Cap: $3.345B info
AMLX
Sep 08, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.88
Real-time Price: $25.55 info
Change: -$8.33 (-25%) info
Market Cap: $3.345B info
AMLX
Aug 20, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $25.55 info
Change: -$14.16 (-36%) info
Market Cap: $3.345B info
AMLX
Aug 20, 2026, 5:27 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $25.55 info
Change: -$14.16 (-36%) info
Market Cap: $3.345B info
AMLX
Aug 19, 2026, 11:06 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $38.45
Real-time Price: $25.55 info
Change: -$12.90 (-34%) info
Market Cap: $3.345B info